DIVERSITY, EQUITY, & INCLUSION
The benefits of research belong to all.
Or so our ideals tell us. Reality tells a different story. Systemic imbalances exclude too many people from trial opportunities on the basis of race, ethnicity, economic status, geography, or other social determinant. The exclusion may not be deliberate, but its effects are dire.
What’s the solution? More complex than any single changemaker can achieve. Drug developers, researchers, clinicians, policymakers, educators, and patient advocates all share the responsibility to achieve our ideals. TriNetX has a role to play. As a research leader, so do you.
Ready to advance your DEI efforts?
Connect with one of our real-world data experts to discuss how TriNetX can guide your DEI efforts into to ground-breaking territories.
The Need for Change
The destination is in sight, but we haven’t reached it.
Black Americans make up roughly 12% of the U.S. population and a disproportionate number of new cancer cases. Yet none of the 11 novel drug approvals for cancer in 2022 were based on study cohorts that enrolled more than 8% Black participants.
Center for Drug Evaluation and Research. Drug Trials Snapshots Summary Report 2022.
Latinos represent 17% of the U.S. population and yet only 6-7% of participants in clinical trials.
S. Presch. Health for All of Us: The Importance of Latino Participation in clinical trials and research. UNIDOS US Blog. 6 March 2018.
Asian American represent 5.9% of the U.S. population and a mean of 1.6% of all participants in pivotal trials between 2015 and 2019.
Lolic M, Araojo R, Okeke M, Woodcock J. Racial and Ethnic Representation in US Clinical Trials of New Drugs and Biologics, 2015-2019. JAMA. 2021;326(21):2201–2203.
Connecting the Dots
Advancing on our Ideals
The barriers to diversity, equity, and inclusion (DEI) are multifacted.
At TriNetX, we’re focusing our strength on three areas…
Turning inclusion criteria into inclusive criteria
Sound experimental design requires that our samples represent the populations we want to understand. Meanwhile, a commitment to patients demands that we extend benefits, if they are discovered, as widely as possible.
Meeting both mandates starts with the right protocol. Study eligibility attuned to the health and experience of today’s patients, representing all backgrounds, let us design trials with more generalizable results. This RWD-informed approach also extends the benefits of participation to those disproportionately excluded by criteria that paint too broad a brush.
Meeting today’s diverse patients where they are
Our federated network of care institutions do more than contribute rich, de-identified data. They stand ready to collaborate with you on trials. After making your criteria “real-world ready”, let our team of clinical analysts and study operations leaders connect you to these institutions over our global platform.
Get to First Patient In on a diverse cohort faster, so you can deliver hope sooner.
Going deep into disparities
Natural course of disease. Disease burden. Standard of care. The forms these take are as various as patients themselves. Trends at the population level can quickly fall apart under analysis by cohort, whether defined clinically or demographically. Our rich de-identified data—inclusive of race, ethnicity, and (for millions of US patients) types of insurance coverage—enable researchers to pierce the surface of the “patient profile” to reveal the critical differences in access, treatment, and outcome.
We don’t stop at gathering the data. We interrogate it, with best-in-class analytic tools and the brightest minds in epidemiology and evidence generation.
As a research leader, you can bring the next chapter of history closer to our ideals. Not with a gesture, but a commitment to best practices. Understanding the social dimension of disease. Scrutizining every criteria of every protocol. Connecting with new care institutions and investigators.
But effective action starts with education. Tell us who you are to access our DEI resources page. There you’ll find:
on-demand webinars featuring thought leaders from Novartis, Takeda, and Sanofi
a library of related publications
the latest FDA guidance on diversity in trial enrollment